The Latest Headlines at American Banking and Market News
Tapestry (NYSE:TPR) PT Raised to $48.00
Tapestry (NYSE:TPR – Free Report) had its price objective upped by Bernstein Bank from $46.00 to $48.00 in a research report sent to investors on Thursday morning. A number of other research firms also recently issued reports... More of this article »
Universal Technical Institute (NYSE:UTI) Given New $20.00 Price Target at Barrington Research
Universal Technical Institute (NYSE:UTI – Free Report) had its target price lifted by Barrington Research from $18.00 to $20.00 in a research note published on Thursday, Benzinga reports. Barrington Research currently has an... More of this article »
HC Wainwright Reiterates “Neutral” Rating for CytomX Therapeutics (NASDAQ:CTMX)
HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) in a research note released on Thursday morning, Benzinga reports. A number of other brokerages have also recently issued... More of this article »
New Fortress Energy (NASDAQ:NFE) Price Target Cut to $43.00
New Fortress Energy (NASDAQ:NFE – Free Report) had its target price trimmed by Stifel Nicolaus from $45.00 to $43.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. A... More of this article »
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price objective hoisted by Stifel Nicolaus from $39.00 to $40.00 in a report released on Thursday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating... More of this article »
Stifel Nicolaus Lowers MasterCraft Boat (NASDAQ:MCFT) Price Target to $25.00
MasterCraft Boat (NASDAQ:MCFT – Free Report) had its target price trimmed by Stifel Nicolaus from $27.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Separately,... More of this article »
KBR (NYSE:KBR) Price Target Raised to $84.00 at Stifel Nicolaus
KBR (NYSE:KBR – Free Report) had its price target upped by Stifel Nicolaus from $83.00 to $84.00 in a report issued on Thursday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the construction company’s... More of this article »
International Seaways (NYSE:INSW) Given New $66.00 Price Target at Stifel Nicolaus
International Seaways (NYSE:INSW – Free Report) had its price target lifted by Stifel Nicolaus from $64.00 to $66.00 in a research note released on Thursday, Benzinga reports. They currently have a buy rating on the transportation... More of this article »
U.S. Physical Therapy (NYSE:USPH) Earns “Outperform” Rating from Barrington Research
Barrington Research reiterated their outperform rating on shares of U.S. Physical Therapy (NYSE:USPH – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $122.00 target price on the... More of this article »
Everi (NYSE:EVRI) Price Target Cut to $11.00 by Analysts at Stifel Nicolaus
Everi (NYSE:EVRI – Free Report) had its price target reduced by Stifel Nicolaus from $12.00 to $11.00 in a research report released on Thursday, Benzinga reports. They currently have a buy rating on the credit services provider’s... More of this article »
Teekay Tankers (NYSE:TNK) Price Target Raised to $76.00
Teekay Tankers (NYSE:TNK – Free Report) had its price objective hoisted by Jefferies Financial Group from $70.00 to $76.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy... More of this article »
C4 Therapeutics (NASDAQ:CCCC) Price Target Raised to $14.00 at Stifel Nicolaus
C4 Therapeutics (NASDAQ:CCCC – Free Report) had its price objective hoisted by Stifel Nicolaus from $13.00 to $14.00 in a report published on Thursday, Benzinga reports. They currently have a buy rating on the stock. Several... More of this article »
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $88.00 by Analysts at Needham & Company LLC
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective decreased by Needham & Company LLC from $90.00 to $88.00 in a research note published on Thursday morning, Benzinga reports. Needham & Company... More of this article »